Why Outlook Therapeutics Stock Surged Today
Shares of Outlook Therapeutics (NASDAQ: OTLK) jumped on Tuesday after the biotech announced positive clinical trial results for its investigational treatment for neovascular age-related macular degeneration (wet AMD). By the close of trading, its stock price was up 6.6% after rising as much as 44.7% earlier in the day.
Outlook Therapeutics' treatment for wet AMD, which is known as ONS-5010/Lytenava (bevacizumab), reached its primary efficacy endpoint in a phase 3 study. A statistically significant 41% of the patients who were treated with bevacizumab gained at least 15 letters in the best-corrected visual acuity (BCVA) at 11 months.
Image source: Getty Images.
Source Fool.com
